Pharmafile Logo
Pharmafocus logo
Advanced Search

Takeda

Showing 15 posts of 249 posts found.

cambridge_skyline

Biogen and Takeda forced to send employees home as coronavirus hits Massachusetts

March 9, 2020
Manufacturing and Production, Medical Communications Biogen, Takeda, coronavirus, pharma

Big pharma has been hit by the coronavirus (COVID-19) outbreak right on its doorstep, as two of the biggest names …

News
takeda_logo_506_small

Positive CHMP approval for Takeda’s Alunbrig in ALK+ advanced non-small lung cancer

March 4, 2020
Research and Development CHMP, EMA, Takeda, lung cancer, pharma

Takeda’s Alunbrig (brigatinib) has been recommended for approval by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human …

News
takeda_usa_pharmaceuticals_u

Takeda’s subcutaneous vedolizumab nabs CHMP nod for maintenance of ulcerative colitis and Crohn’s

February 28, 2020
Medical Communications, Sales and Marketing CHMP, EMA, Takeda, vedolizumab

Takeda’s subcutaneous formulation of its gut-selective biologic vedolizumab has secured recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal …

News
hqdefault

Takeda acquires PvP Biologics after successful Phase 1 study of Celiac Disease treatment

February 26, 2020
Research and Development Celiac, PvP, Takeda, phase 1, phase III

Takeda has acquired PvP Biologics following the conclusion of a Phase 1 study of the investigational medicine TAK-062 for the …

News
entrance_takeda_i020_v1

Strong Phase 3 data for Takeda’s subcutaneous Entyvio in moderate to severe Crohn’s disease

February 17, 2020
Research and Development, Sales and Marketing Crohn’s disease, Entyvio, Takeda, crohn's disease, pharma

Takeda has shared positive new Phase 3 data on a subcutaneous formulation of its gut-selective biologic Entyvio (vedolizumab) as a …

News
china_block_001_takeda_0

Takeda commits to advancing treatments for rare bleeding disorders and cancer

December 10, 2019
Manufacturing and Production, Research and Development ASH 19, Cancer, Takeda, lymphoma, oncology

Takeda presented at the 61st American Society of Hematology (ASH) Annual Meeting, 29 company-sponsored abstracts to highlight its commitment to …

News

Takeda’s Ninlaro shows progression-free survival benefit in multiple myeloma

November 8, 2019
Medical Communications, Research and Development Ninlaro, Takeda, multiple myeloma, pharma

Takeda has revealed strong new findings for Ninlaro (ixazomib), confirming that the therapy met its primary endpoint as a first-line …

News
takeda_usa_pharmaceuticals_u

Strong Phase 3 showing for Takeda’s dengue vaccine, but concerns remain over consistent coverage

November 7, 2019
Research and Development Takeda, dengue, pharma

Takeda has unveiled new data from its ongoing Phase 3 trial investigating the efficacy of its vaccine candidate TAK-003 in …

News
takeda_usa_pharmaceuticals_u

Takeda to jettison non-core asset portfolio to Stada for $660 million

November 6, 2019
Research and Development, Sales and Marketing Stada, Takeda, pharma

Takeda has announced it is divesting a portfolio of its over-the-counter (OTC) and prescription drug products to Stada for a …

News

Redefining the value of medicines with patients at the centre

November 4, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Takeda, health economics and outcomes research, market access, pharma

Liz Lewis, Head of Global Oncology Patient Value, Policy and Access at Takeda Oncology, discusses the importance and challenges of …

Feature
takeda_deerfield_hq

Takeda’s Entyvio outperforms AbbVie’s Humira in moderate-to-severe ulcerative colitis

September 27, 2019
Medical Communications, Research and Development AbbVie, Entyvio, Humira, Takeda, pharma, ulcerative colitis

Takeda has released strong new data for Entyvio (vedolizumab), showing that the gut-selective biologic outperformed AbbVie’s blockbuster anti-tumour necrosis factor-alpha …

News
takeda_world

Takeda’s investigational therapy shows promise as cytomegalovirus treatment

September 25, 2019
Research and Development, Sales and Marketing Takeda, cytomegalovirus, maribavir, pharma

New Phase 2 data has been released on Takeda’s investigational antiviral therapy TAK-620 (maribavir) in patients with cytomegalovirus (CMV) infection …

News
japan-112722_640

Lundbeck and Takeda’s depression drug approved in Japan

September 20, 2019
Medical Communications, Sales and Marketing Japan, Lundbeck, Takeda, major depressive disorder, pharma

Takeda and Lundbeck have announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has chosen to authorise their drug …

News

NICE recommends Takeda’s Takhzyro for NHS use to prevent hereditary angioedema attacks

September 18, 2019
Research and Development, Sales and Marketing NHS, NICE, Takeda, Takhzyro, pharma

UK drug watchdog NICE has announced its final draft guidance recommending Takeda’s subcutaneous injection Takhzyro (Lanadelumab) for use on the …

News

Takeda signs deal with Sosei Heptares worth $1.2 billion

August 6, 2019
Manufacturing and Production GPCR, Sosei Heptares, Takeda, pharma, sosei

Takeda has entered into a partnership with Sosei Heptares to develop drugs that modulate G protein-coupled receptor (GPCR) targets. The …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025